Effect of Clomiphene Citrate on Fertility Hormones in Women with Polycystic Ovarian Syndrome
Abstract
Abstract Views: 0
This study aims to investigate the positive effect of Clomiphene Citrate (CC) in inducing ovulation in women with PCOS. Clomiphene Citrate is a non-steroidal drug that primarily affects estrogen production. CC also has pronounced effects on balancing of the female hormones, normal ovulation process, and overcoming the PCOS-based infertility issues. Hormonal profile evaluation including follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone, and estrogen was performed at Clinical Laboratory, Services Hospital, Lahore. Serum volume of the aforementioned hormones were determined in PCOS-suffering infertile women (n=50) and healthy fertile women (n=50) by using a commercially available ELISA kit manufactured by Calbotech lnc. Serum luteinizing hormone (LH), follicle stimulating hormone (FSH), progesterone, and estrogen mean values in PCOS patients before the use of CC were evaluated as 5.74±0.939 (IU/L), 3.804±1.163 (IU/L), 2.098±1.233 (ng/ml), and (51.458±7.091 pg/ml respectively, while after management with CC the mean value of serum LH, FSH, Progesterone, and Estrogen were 3.716±0.513 (IU/L), 5.644±1.130 (IU/L), 10.704±2.313 ng/ml and 37.72±4.969 pg/ml respectively, which indicated a significant differences in hormonal pattern . The current study demonstrates that Clomiphene Citrate (CC) has positive effects in ovulation process in females with polycystic ovarian syndrome (PCOS), within the local population.
Downloads
References
Kolesnikova L, Kolesnikov S, Darenskaya M, et al. Activity of LPO processes in women with polycystic ovarian syndrome and infertility. Bull Exp Biol Med. 2017;162(3):320–322. https://doi.org/10.1007/s10517-017-3605-5
Corte LD, Foreste V, Barra F, et al. Current and experimental drug therapy for the treatment of polycystic ovarian syndrome. Expert Opin Invest Drugs. 2020;29(8):819–830. https://doi.org/10.1080/13543784.2020.1781815
Zhao X, Jiang Y, Xi H, Chen L, Feng X. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a review. Geburtshilfe Frauenheilkd. 2020;80(02):161–171.
Abbott DH, Dumesic DA, Levine JE. Hyperandrogenic origins of polycystic ovary syndrome–implications for pathophysiology and therapy. Expert Rev Endocrinol Metab. 2019;14(2):131–143. https://doi.org/10.1080/17446651.2019.1576522
Homburg R. Clomiphene citrateend of an era? A mini-review. Hum Reprod. 2005;20(8):2043–2051. https://doi.org/10.1093/humrep/dei042
Imani B, Eijkemans MJ, te Velde ER, Habbema JDF, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77(1):91–97. https://doi.org/10.1016/S0015-0282(01)02929-6
Chandrasekaran S, Sagili H. Metabolic syndrome in women with polycystic ovary syndrome. Obstet Gynaecol. 2018;20(4):245–252. https://doi.org/10.1111/tog.12519
Greenwood EA, Pasch LA, Shinkai K, Cedars MI, Huddleston HG. Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: results of a longitudinal study. Fertil Steril. 2019;111(1):147–156. https://doi.org/10.1016/j.fertnstert.2018.10.004
Kini S. Polycystic ovary syndrome: diagnosis and management of related infertility. Obstet Gynaecol Reprod Med. 2012;22(12):347–353. https://doi.org/10.1016/j.ogrm.2012.10.003
Gadalla M, Huang S, Wang R, et al. Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in anovulatory women: systematic review and meta‐analysis. Ultrasound Obstet Gynecol. 2018;51(1):64–76. https://doi.org/10.1002/uog.18933
Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97(1):28–38. https://doi.org/10.1016/j.fertnstert.2011.09.024
Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome—beyond ovulation induction. Hum Reprod. 2002;17(12):3016–3026. https://doi.org/10.1093/humrep/17.12.3016
Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril. 2010;93(6):1864–1869. https://doi.org/10.1016/j.fertnstert.2008.12.024
Morishita M, Endo T, Baba T, et al. Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. J Ovarian Res. 2018;11(1):1–8. https://doi.org/10.1186/s13048-018-0395-y
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–16018. https://doi.org/10.1093/humrep/dey256
Soldin OP, Hoffman EG, Waring MA, Soldin SJ. Pediatric reference intervals for FSH, LH, estradiol, T3, free T3, cortisol, and growth hormone on the DPC IMMULITE 1000. Clin Chim Acta. 2005;355(1-2):205–210. https://doi.org/10.1016/j.cccn.2005.01.006
Qiu Q, Kuo A, Todd H, et al. Enzyme immunoassay method for total urinary follicle-stimulating hormone (FSH) beta subunit and its application for measurement of total urinary FSH. Fertil Steril. 1998;69(2):278–285. https://doi.org/10.1016/S0015-0282(97)00475-5
Williamson M, Viau V. Androgen receptor expressing neurons that project to the paraventricular nucleus of the hypothalamus in the male rat. J Comp Neurol. 2007;503(6):717–740. https://doi.org/10.1002/cne.21411
Tietz N. Clinical guide to laboratory tests. WB Sannders, Co. Phila. 1995.
Al-Inany H, Azab H, El-Khayat W, Nada A, El-Khattan E, Abou-Setta AM. The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial. Fertil Steril. 2010;94(6):2167–2171. https://doi.org/10.1016/j.fertnstert.2010.01.069
Kawwass JF, Loucks TL, Berga SL. An algorithm for treatment of infertile women with polycystic ovary syndrome. Middle East Fertil Soc J. 2010;15(4):231–239. https://doi.org/10.1016/j.mefs.2010.07.010
Ainehchi N, Khaki A, Ouladsahebmadarek E, et al. The effect of clomiphene citrate, herbal mixture, and herbal mixture along with clomiphene citrate on clinical and para-clinical parameters in infertile women with polycystic ovary syndrome: a randomized controlled clinical trial. Arch Med Sci. 2020;16(6):1304–1318. https://doi.org/10.5114/aoms.2020.93271
Ayaz A, Alwan Y, Farooq MU. Metformin—clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome. J Hum Reprod Sci. 2013;6(1):15–18. https://doi.org/10.4103/0974-1208.112372
Dupont J, Scaramuzzi RJ. Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle. Biochem J. 2016;473(11):1483–1501. https://doi.org/10.1042/BCJ20160124
Porter DT, Moore AM, Cobern JA, et al. Prenatal testosterone exposure alters GABAergic synaptic inputs to GnRH and KNDy neurons in a sheep model of polycystic ovarian syndrome. Endocrinology. 2019;160(11):2529–2542. https://doi.org/10.1210/en.2019-00137
Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708. https://doi.org/10.1093/humupd/dmw025
The Royal College of Obstetricians and Gynaecologists. Fertility: assessment and treatment for people with fertility problems. https://www.ncbi.nlm.nih.gov/books/NBK247932/pdf/Bookshelf_NBK247932.pdf. Published 2013. Accessed December 6, 2023.
ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update. 2012;18(5):586–599. https://doi.org/10.1093/humupd/dms019
Rees DA, Jenkins-Jones S, Morgan CL. Contemporary reproductive outcomes for patients with polycystic ovary syndrome: a retrospective observational study. J Clin Endocrinol Metab. 2016;101(4):1664–1672. https://doi.org/10.1210/jc.2015-2682
Bruyneel A, Catteau-Jonard S, Decanter C, et al. Polycystic ovary syndrome: what are the obstetrical risks? Gynecol Obstet Fertil. 2014;42(2):104–111. https://doi.org/10.1016/j.gyobfe.2014.01.001
Copyright (c) 2024 Asma Arshad, Kashif Ur Rehman, Hamama Islam Butt, Shahzad Bashir, Fatima Umar, Zahida Yaseen, Kashish Zahra, Ahmad Bakhsh
This work is licensed under a Creative Commons Attribution 4.0 International License.
